tiapridal 5 mg/dose druppels opl.
sanofi belgium sa-nv - tiapridehydrochloride 5,55 mg/dosis - eq. tiapride 5 mg/dosis - druppels voor oraal gebruik, oplossing - 5 mg/dose - tiapridehydrochloride 5.55 mg/dosis - tiapride
vinorelbin eugia 10 mg/ml inf. opl. (conc.) i.v. flac.
eugia pharma (malta) ltd. - vinorelbinetartraat 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - vinorelbinetartraat 13.85 mg/ml - vinorelbine
vinorelbin eugia 10 mg/ml inf. opl. (conc.) i.v. flac.
eugia pharma (malta) ltd. - vinorelbinetartraat 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - vinorelbinetartraat 13.85 mg/ml - vinorelbine
vinorelbine accord healthcare 10 mg/ml inf. opl. (conc.) i.v. flac.
accord healthcare b.v. - vinorelbinetartraat 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - vinorelbinetartraat 13.85 mg/ml - vinorelbine
vinorelbine accord healthcare 10 mg/ml inf. opl. (conc.) i.v. flac.
accord healthcare b.v. - vinorelbinetartraat 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - vinorelbinetartraat 13.85 mg/ml - vinorelbine
sevikar hct 20 mg/5 mg/12,5 mg filmomhulde tabletten
amlodipinebesilaat samenstelling overeenkomend met ; amlodipine ; hydrochloorthiazide ; olmesartanmedoxomil - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd ; polyvinylalcohol (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171)
hyperiplant 300 mg omh. tabl.
dr. willmar schwabe gmbh & co. kg - omhulde tablet
nebivolol/hct eg 5 mg - 12.5 mg filmomh. tabl.
eg sa-nv - nebivololhydrochloride 5,45 mg - eq. nebivolol 5 mg; hydrochloorthiazide 12,5 mg - filmomhulde tablet - nebivolol and thiazides
nebivolol/hct eg 5 mg - 25 mg filmomh. tabl.
eg sa-nv - nebivololhydrochloride 5,45 mg - eq. nebivolol 5 mg; hydrochloorthiazide 25 mg - filmomhulde tablet - nebivolol and thiazides
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicine hydrochloride - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastische middelen - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).